Novo Nordisk
Wegovy (Semaglutide 2.4mg)
$1,350.004 pens/month (2.4mg/0.5ml per dose)($337.50/pen)Injectable
FDA-approved once-weekly injectable for chronic weight management; the most clinically proven peptide intervention for obesity with 15–17% average body weight reduction in STEP trials. PRESCRIPTION REQUIRED.
Community Rating
4.3★/ 5.0
Concentration
2.4mg/0.5ml semaglutide
Peptides in this product
Other key ingredients
Semaglutide 2.4mg (GLP-1 receptor agonist)Disodium phosphate dihydratePropylene glycolPhenolWater for injections
Pros
- ✓FDA-approved for chronic weight management (BMI 30+ or 27+ with weight-related condition)
- ✓STEP clinical trials showed 15–17% average body weight reduction over 68 weeks
- ✓Once-weekly subcutaneous injection — simple dosing schedule
- ✓Documented cardiovascular benefit data (SELECT trial showed 20% reduction in MACE)
Cons
- ✗Prescription only — requires physician assessment, diagnosis, and ongoing monitoring
- ✗List price ~$1,350/month without insurance; access and coverage vary widely
- ✗Common GI side effects: nausea, vomiting, diarrhoea, constipation — particularly during dose escalation
- ✗Weight typically returns after discontinuation without sustained lifestyle changes
- ✗Rare but serious risks: pancreatitis, gallbladder disease, and contraindicated in personal/family history of medullary thyroid carcinoma or MEN2
Last verified: 2025-03-01
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.